Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties

Journal of Medicinal Chemistry

Volumn 51, Issue 2, 2008, Pages 314-323

  Engel, Dikla ^a,b   Nudelman, Abraham ^a   Tarasenko, Nataly ^b   Levovich, Inesa ^a,b   Makarovsky, Igor ^a   Sochotnikov, Segev ^a   Tarasenko, Igor ^b   Rephaeli, Ada ^b  

^a BAR ILAN UNIVERSITY   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

5 FLUORO 1 (TETRAHYDRO 2 FURANY1) 2,4(1H,3H) PYRIMIDIONE; ACETYLCYSTEINE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; BUTYRIC ACID; BUTYROYLOXYMETHYL DERIVATIVE; FLUOROURACIL DERIVATIVE; FORMALDEHYDE; MATRIGEL; PRODRUG; REACTIVE OXYGEN METABOLITE; TEGAFUR; UNCLASSIFIED DRUG;

ACYLOXYMETHYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASSAY; BREAST CARCINOMA; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER THERAPY; CELL LINE; CELL VIABILITY; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DEGRADATION; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; HYDROLYSIS; HYDROXYMETHYLATION; IC 50; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MALE; MATRIGEL ASSAY; METASTASIS; METHYLATION; MOUSE; NONHUMAN; STATISTICAL ANALYSIS; STRUCTURE ACTIVITY RELATION; TUMOR GROWTH; TUMOR XENOGRAFT;

ACETYLCYSTEINE; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; ASTROCYTES; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FORMALDEHYDE; HISTONE ACETYLTRANSFERASES; HUMANS; MALE; METHYLATION; MICE; MICE, INBRED BALB C; MICE, INBRED ICR; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PRODRUGS; SEMICARBAZIDES; STRUCTURE-ACTIVITY RELATIONSHIP; TEGAFUR; TRANSPLANTATION, HETEROLOGOUS; UMBILICAL CORD;

EID: 38349093869     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm7009827     Document Type: Article

References (25)

1. Rephaeli, A.; Rabizadeh, E.; Aviram, A.; Shaklai, M.; Ruse, M.; Nudelman, A. Derivatives of butyric acid as potential anti-neoplastic agents. Int. J. Cancer 1991, 49, 66-72.
2. Nudelman, A.; Ruse, M.; Aviram, A.; Rabizadeh, E.; Shaklai, M.; Zimrah, Y.; Rephaeli, A. Novel anticancer prodrugs of butyric acid. J. Med. Chem. 1992, 35, 687-694.
3. Nudelman, A.; Gnizi, E.; Katz, Y.; Azulai, R.; Cohen-Ohana, M.; Fibach, E.; Prus, E.; Sampson, R. S.; Langzam, L.; Pugach, V.; Rephaeli, A. Prodrugs of butyric acid (III). Novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases. Eur. J. Med. Chem. 2001, 36, 63-74.
4. Rephaeli, A.; Zhuk, R.; Nudelman, A. Butyric acid prodrugs from bench to bedside: Synthetic design, mechanisms of action and clinical applications. Drug Dev. Res. 2000, 50, 379-391.
5. Nudelman, A.; Levovich, I.; Cutts, S. M.; Phillips, D. R.; Rephaeli, A. The role of intracellularly released formaldehyde and butyric acid in the anticancer activity of acyloxyalkyl esters. J. Med. Chem. 2005, 48, 1042-1054.
6. Kasukabe, T.; Rephaeli, A.; Honma, Y. An anticancer derivative of BA (pivalyloxymethyl-butyrate) and daunorubicin cooperatively prolong survival of mice inoculated with monocytic leukemia cells. Br. J. Cancer. 1997, 75, 850-854.
7. Batova, A.; Shao, L.; Diccianni, M. B.; Yu, A. L.; Tanaka, T.; Rephaeli, A.; Nudelman, A.; Yu, J. The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. Blood 2002, 100, 3319-3324.
8. Kalasz, H. Biological role of FA, and cycles related to methylation, demethylation, and FA production. Mini-Rev. Med. Chem. 2003, 3, 175-192.
9. Tyihak, E.; Bocsi, J.; Timar, F.; Racz, G.; Szende, B. Formaldehyde promotes and inhibits the proliferation of cultured tumor and endothelial cells. Cell Proliferation 2001, 34, 135-141.
10. Cutts, S. M.; Nudelman, A.; Rephaeli, A.; Phillips, D. R. The power and potential of doxorubicin-DNA adducts. IUBMB Life 2005, 57, 73-81.
11. Cutts, S. M.; Swift, L. P.; Rephaeli, A.; Nudelman, A.; Phillips, D. R. Recent advances in understanding and exploiting the activation of anthracyclines by FA. Curr. Med. Chem. 2005, 5, 1-14.
12. Engel, D.; Nudelman, A.; Levovich, I.; Gruss-Fischer, T.; Entin-Meer, M.; Phillips, D. R.; Cutts, S. M.; Rephaeli, A. Mode of interaction between butyroyloxymethyl-diethyl phosphate (AN-7) and doxorubicin in MCF-7 and resistant MCF-7/Dx cell lines. J. Cancer Res. Clin. Oncol. 2006, 132, 673-683.
13. Taatjes, D. J.; Fenick, D. J.; Koch, T. H. Epidoxoform: A hydrolytically more stable anthracycline-formaldehyde conjugate toxic to resistant tumor cells. J. Med. Chem. 1998, 41, 1306-1314.
14. Rephaeli, A.; Waks-Yona, S.; Nudelman, A.; Tarasenko, I.; Tarasenko, N.; Phillips, D. R.; Cutts, S. M.; Kessler-Icekson, G. Anticancer prodrugs of butyric acid and formaldehyde protect against doxorubicin-induced cardiotoxicity. Br. J. Cancer 2007, 96, 1667-1674.
15. Malet-Martino, M.; Martino, R. Clinical studies of three oral prodrugs of 5-fluorouracil (Capecitabine, UFT, S-1): A review. Oncologist 2002, 7, 288-323.
16. Schoffski, P. The modulated oral fluoropyrimidine prodrug S-1 and its use in gastrointestinal cancer and other solid tumors. Anti-Cancer Drugs 2004, 15, 85-106.
17. Cutts, S. M.; Rephaeli, A.; Nudelman, A.; Hmelnitsky, I.; Phillips, D. R. Molecular basis for the synergistic interaction of adriamycin with the formaldehyde releasing prodrug pivaloyloxymethyl butyrate (AN-9). Cancer Res. 2001, 61, 8194-8202.
18. Bras-Goncalves, R. A.; Pocard, M.; Formento, J. L.; Poirson-Bichat, F.; De pinieux, G.; Pandrea, I.; Arvelo, F.; Ronco, G.; Villa, P.; Coquelle, A.; Milano, G.; Lesuffleur, T.; Dutrillaux, B.; Poupon, M. F. Synergistic efficacy of n-butyrate and 5-fluorouracil in human colorectal cancer xenografts via modulation of DNA synthesis. Gastroenterology 2001, 120, 874-888.
19. Cordel, S.; Heymann, M. F.; Boisteau, O.; Oliver, L.; Le Pendu, J.; Gre'Goire, M.; Meflah, K. 5-Fluorouracil-resistant colonic tumors are highly responsive to sodium butyrate/interleukin-2 bitherapy in rats. Int. J. Cancer 1997, 73, 924-928.
20. Khaw, P. T.; Ward, S.; Porter, S.; Grierson, I.; Hitchings, R. A.; Rice, N. S. The long-term effects of 5-fluorouracil and sodium butyrate on human Tenon's fibroblasts. Invest. Ophthalmol. Visual Sci. 1992, 33, 2043-2052.
21. Yu, P. H.; Wright, S.; Fan, E. H.; Lun, Z. R.; Gubisne-Harberle, D. Physiological and pathological implications of semicarbazide-sensitive amine oxidase. Biochim. Biophys. Acta 2003, 1647, 193-199.
22. Swift, L. P.; Cutts, S. M.; Rephaeli, A.; Nudelman, A.; Phillips, D. R. Activation of adriamycin by the pH-dependent formaldehyde releasing prodrug hexamethylenetetramine. Mol. Cancer Ther. 2003, 2, 189-198.
23. Denk, H.; Moldeus, P. W.; Schulz, R. A.; Schenkman, J. B.; Keyes, S. R.; Cinti, D. L. Hepatic organelle interaction. IV. Mechanism of succinate enhancement of FA accumulation from endoplasmic reticulum N-dealkylations. J. Cell Biol. 1976, 69, 589-598.
24. McCaffrey, T. A.; Agarwal, L. A.; Weksler, B. B. A rapid fluorometric DNA assay for the measurement of cell density and proliferation in vitro. In Vitro Cell. Dev. Biol. 1988, 24, 247-252.
25. Nuydens, R.; Novalbos, J.; Dispersyn, G.; Weber, C.; Borgers, M; Geerts, H. A rapid method for the evaluation of compounds with mithochondria-protective properties. J. Neurosci. Methods 1999, 92, 153159.